Skip to main content
. 2020 May 7;9(10):e014761. doi: 10.1161/JAHA.119.014761

Figure 5. Effects of periaortic leptin antagonist (LepA) application on left ventricular (LV) systolic function and morphological features.

Figure 5

Echocardiographic assessment of LV dimensions at baseline (7 weeks) and after 4 weeks at 30 days postoperatively (POD30). A, End diastolic diameter (EDD). Note, EDD assessed 4 weeks postoperatively was increased in LepA‐treated Marfan syndrome (MFS) vs baseline and MFS, ††, P<0.01 and *P<0.05, respectively. B, End systolic diameter (ESD). Note, ESD increased in MFS mice on POD30 compared with baseline and wild type (WT) at 4 weeks, ††† P<0.001 and *P<0.05, respectively. There was a moderate ESD increase in LepA‐treated MFS mice vs baseline and vs MFS, † and *, P<0.05, for both. C, Fractional shortening (FS) percentage. Note that FS percentage in LepA‐treated MFS animals remained comparable to that in WT mice, but decreased in MFS mice (††† and ***, P<0.001 vs baseline and MFS, respectively). D, Fractional area change (FAC) percentage. On POD30, FAC percentage remained stable in LepA‐treated MFS and WT mice (11 weeks), but was markedly decreased in MFS mice. LepA‐treated MFS, WT, and basal MFS vs 4 weeks MFS †††, P<0.001 vs Baseline, ***, P<0.001 vs MFS E, Ejection fraction (EF) percentage. Note that 4 weeks postoperatively, EF percentage remained stable in LepA‐treated MFS and untreated WT mice, but was markedly decreased in MFS mice. LepA‐treated MFS, WT, and basal MFS vs MFS on POD30, †††, P<0.001 vs Baseline, ***, P<0.001 vs MFS. F, Systolic blood pressure (Sys BP). Note, LepA‐treated MFS mice exhibit normalization of Sys BP compared with MFS animals on POD30, ††, P<0.01. BP was not measured in WT mice.